We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Biologic Production and Host Cell Proteins

Host cell proteins can trigger unwanted immunogenic responses, leading to safety and stability concerns in biologics.

Article  
Last Updated: November 10, 2023 
(+ more)
Published: November 7, 2023
Written by 
Aron Gyorgypal, PhD
Antibodies
Credit: iStock

Biologic therapies have transformed modern medicine, but their production in mammalian systems, particularly Chinese hamster ovary (CHO) cells, introduces challenges related to host cell proteins (HCPs). If not adequately managed, these impurities can compromise drug safety and efficacy.​


This article examines the complexities of HCP contamination in biologic manufacturing. Continue reading to discover the importance of advanced analytical techniques for HCP detection and strategies to mitigate their impact.​

Sponsored by

Meet the Author
A greyscale headshot of Aron Gyorgypal
Aron Gyorgypal, PhD
Postdoctoral Research Fellow
Dr. Aron Gyorgypal is a postdoctoral research fellow at Harvard Medical School and Massachusetts General Hospital in Boston, Massachusetts. Following the completion of his PhD, he joined the Anthony Lab at Harvard Medical School and Massachusetts General Hospital in the immunology department, where he leverages his engineering skillset to deepen the understanding of immunological disorders and develop therapeutic solutions against such conditions.
View this Article for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter